Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126736 · ClinicalTrials.gov registry record · Phase 1
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT01126736 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 98 participants.
The verdict
NCT01126736, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Eribulin Mesylate Administered in Combination with Pemetrexed is safe and tolerable and to gain a preliminary indication of clinical benefit when administered to Patients with Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer.
Interventions
- DRUG pemetrexed
- DRUG eribulin mesylate
- DRUG Eribulin mesylate (eribulin; E7389)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2010-06-10 |
| Est. Completion | 2015-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01126736
The ClinicalTrials.gov registry entry for NCT01126736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pemetrexed is the first listed.
NCT01126736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01126736 about?
NCT01126736 is a clinical study titled "Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer". The purpose of this study is to determine whether Eribulin Mesylate Administered in Combination with Pemetrexed is safe and tolerable and to gain a preliminary indication of clinical benefit when administered to Patients with Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer.
What is the current status of trial NCT01126736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2010-06-10. Estimated completion is 2015-03-18.
What interventions are being tested in trial NCT01126736?
The interventions under investigation include: pemetrexed (DRUG), eribulin mesylate (DRUG), Eribulin mesylate (eribulin; E7389) (DRUG).
Who is sponsoring clinical trial NCT01126736?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.